Cell Therapy as Treatment for Cerebral Palsy
Phase 1
Withdrawn
- Conditions
- Cerebral Palsy
- Registration Number
- NCT02241395
- Lead Sponsor
- Neurogen Brain and Spine Institute
- Brief Summary
The purpose of this study was to study the effect of autologous bone marrow mononuclear cells on common symptoms of cerebral palsy patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- diagnosed cases of any type of Cerebral Palsy
- age above 6 months.
Exclusion Criteria
- presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/ Hepatitis C Virus
- malignancies
- bleeding tendencies
- pneumonia
- renal failure
- severe liver dysfunction
- severe anemia [Hemoglobin < 8]
- any bone marrow disorder
- space occupying lesion in brain
- other acute medical conditions such as respiratory infection and pyrexia.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method change in clinical symptoms over a period of 2 years 2 years Clinical symptoms such as oromotor skills, sitting and standing balance, speech, ambulation, muscle tone, cognition, hand and leg movement, walking, etc
- Secondary Outcome Measures
Name Time Method Change in GMFM score 1 year Change in Gross Motor Function Measure 1 year
Trial Locations
- Locations (1)
Neurogen brain and spine institute
🇮🇳Navi Mumbai, Maharashtra, India
Neurogen brain and spine institute🇮🇳Navi Mumbai, Maharashtra, India